The U.S. Food and Drug Administration granted approval to Seattle Genetics Inc.’s Tukysa tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Atomwise, a leader in using artificial intelligence for small-molecule discovery, and Bridge Biotherapeutics, a clinical-stage biotech company, announced a research collaboration to launch up to 13 small-molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.

Stuart Hughes was named CEO of Pathios Therapeutics Ltd.

Researchers at the University of Helsinki identified a molecule called BT13 that potentially can increase levels of dopamine.

A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.

An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.

The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.

Acceleron Pharma and Fulcrum Therapeutics enter 2020 as partners to tackle pulmonary diseases.

FreshBlood Group’s Bob Finkel shares his thoughts on various industry topics including the youth vaping epidemic and the complexities in promoting CBD-based products.

Bayer announced a three-year collaboration agreement with Children’s Hospital of Philadelphia (CHOP) for the discovery and development of small molecules to develop a first-in-class oral non-replacement therapy for the treatment of hemophilia A and B.